miR-128-3p is known to regulate drug resistance by targeting various genes, including c-Met, MUC1-C, BMI-1, and ABCC5 in hepatocellular carcinoma [54], glioma [55], lung cancer [56], and ovarian cancer [57]. This evidence concerns the gene ABCC5 and central nervous system cancer.